SynthesisTargeted oncology2026

Can PARP Inhibitors Benefit Patients with Homologous Recombination Repair-Proficient Castration-Resistant Prostate Cancer? A Meta-analysis.

Susu Zhou et al.PubMed ↗Publisher ↗

No numbers read from the abstract.